|Institutional Source||Beutler Lab|
|Gene Name||prostaglandin-endoperoxide synthase 1|
|Synonyms||Pghs1, Cox-3, COX1, Cox-1, cyclooxygenase 1|
|Is this an essential gene?||Possibly non essential (E-score: 0.457)|
|Stock #||R6979 (G1)|
|Chromosomal Location||36230426-36252272 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 36251299 bp|
|Amino Acid Change||Aspartic acid to Glycine at position 586 (D586G)|
|Ref Sequence||ENSEMBL: ENSMUSP00000059977 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000062069]|
|Predicted Effect||probably benign
AA Change: D586G
PolyPhen 2 Score 0.000 (Sensitivity: 1.00; Specificity: 0.00)
AA Change: D586G
|Meta Mutation Damage Score||0.1527|
|Coding Region Coverage||
|Validation Efficiency||100% (50/50)|
FUNCTION: This is one of two genes encoding similar enzymes that catalyze the conversion of arachinodate to prostaglandin. The encoded protein regulates angiogenesis in endothelial cells, and is inhibited by nonsteroidal anti-inflammatory drugs such as aspirin. Based on its ability to function as both a cyclooxygenase and as a peroxidase, the encoded protein has been identified as a moonlighting protein. [provided by RefSeq, Jan 2014]
PHENOTYPE: Null mutants show impaired platelet aggregation, reduced inflammatory responses, and diminished susceptibility to induced papillomas. Female mutants exhibit delayed parturition and their offspring die neonatally. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ptgs1||
(F):5'- CAGCCCAACTCCATCTTTGG -3'
(R):5'- ACAATATTCTAGGCAAGGGTAAGACC -3'
(F):5'- TATGATAGAGATGGGGGCTCC -3'
(R):5'- GACCCAAAGTTTCAAATGTGAGC -3'